A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

PURPOSE: AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (Part B) on the PK/safety of the tablet. METHODS: Ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Dean, Emma, Banerji, Udai, Schellens, Jan H. M., Krebs, Matthew G., Jimenez, Begona, van Brummelen, Emilie, Bailey, Chris, Casson, Ed, Cripps, Diana, Cullberg, Marie, Evans, Stephen, Foxley, Andrew, Lindemann, Justin, Rugman, Paul, Taylor, Nigel, Turner, Guy, Yates, James, Lawrence, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5907623/
https://ncbi.nlm.nih.gov/pubmed/29541803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3558-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados